Your trusted source for investing success

Tag: Patents

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued to DelMar, United States Patent No. 9,759,698 covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083).

DelMar’s new patent strengthens the Company’s control over

American Manganese Inc. Updates Lithium Ion Battery Recycling and Discusses Metal Markets

American Manganese Inc. Updates Lithium Ion Battery Recycling and Discusses Metal Markets

Larry W. Reaugh, President and Chief Executive Officer of American Manganese Inc. (TSXV:AMY; PINKS:AMYZF;FRANK:2AM) , is pleased to announce that Kemetco has now completed the successful production of rechargeable lithium ion batteries from recycled Lithium Manganese Oxide (LMO), Lithium Cobalt Oxide (LCO), Lithium Nickel Manganese Cobalt Oxide (NMC) and Lithium Nickel Cobalt Aluminum Oxide

Nemaska Lithium Added to S&P/TSX Canadian Indices

Nemaska Lithium Added to S&P/TSX Canadian Indices

Nemaska Lithium Inc. (TSX:NMX,OTCQX:NMKEF) announced today that, effective September 18, 2017, it has been added to S&P/TSX Canadian Indices including: the S&P/TSX SmallCap Index, S&P/TSX Global Mining Index, S&P/TSX Global Base Metals Index and the S&P/TSX Equal Weight Global Base Metals Index.

Guy Bourassa, President and CEO of Nemaska Lithium commented, “Our

InMed Files Provisional Patent

InMed Pharmaceuticals announced the filing of a provisional patent application pertaining to the Company’s proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature.

RespireRx Pharmaceuticals Inc. to Present at 2017 Rodman & Renshaw Conference

RespireRx Pharmaceuticals Inc. to Present at 2017 Rodman & Renshaw Conference

RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders, including sleep apnea, opioid-induced respiratory depression, and respiratory insufficiency due to spinal cord injury, announces that the Company’s Chief Executive Officer and Vice Chairman of the Board of Directors, James

Canadian Marijuana Stocks

Canadian Marijuana Stocks

The Canadian marijuana sector is one of the hottest growing sectors. Here’s a look at Canadian cannabis companies for investors to consider.

Naturally Splendid presenting at the Global Chinese Financial Forum

Naturally Splendid presenting at the Global Chinese Financial Forum

President, Director, & Founder of Naturally Splendid (TSXV:NSP) Enterprises Ltd. J. Craig Goodwin, presented at the Global Chinese Financial Forum, in Shanghai. 

Please use the link below to view the 30 minute presentation:

 

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a biotechnology and consumer products company that is developing, producing, commercializing, and licensing an

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria’s TurboCBDTM.

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria’s TurboCBDTM.

Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) announces the world’s first clinical study on human volunteers of cannabidiol  (CBD) within Lexaria’s high absorption TurboCBD™ product, to evaluate its effects on both cardiovascular health and cognitive function.

The study will have a double-blind and placebo controlled cross-over design measuring effects both after a single dose,

Isodiol International Inc. Provides Sponsorship At The US Autism & Asperger Association Conference

Isodiol International Inc. Provides Sponsorship At The US Autism & Asperger Association Conference

Isodiol International Inc. (CSE:ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator, specializing in the development of pharmaceutical and consumer products, announces it proudly exhibited at the US Autism & Asperger Association (USAAA) (http://usautism.org/conferences/schedule.html) conference this past weekend in Portland, Oregon and sponsored Dr. Ronald Aung-Din to educate

Naturally Splendid Reports Second Quarter Sales for 2017

Naturally Splendid Reports Second Quarter Sales for 2017

Naturally Splendid (TSXV:NSP) is pleased to announce its financial results for the second quarter ended June 30th , 2017. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards.

Naturally Splendid recorded sales of $481,746 and $1,068,949 during the three and six months ended June 30, 2017, compared to

RespireRx Pharmaceuticals Inc. Files June 30, 2017 Quarterly Report on Form 10-Q And Provides Update

RespireRx Pharmaceuticals Inc. Files June 30, 2017 Quarterly Report on Form 10-Q And Provides Update

RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of neurologically controlled respiratory disorders, including obstructive sleep apnea and opioid induced respiratory depression (a form of central apnea) and other respiratory and neurological conditions, has filed its June 30, 2017 Quarterly Report

"Ready to start investing in Cannabis? Get your Investor guide today"

Click below to get an INN Insider's Report on marijuana investing (value of $49) for FREE. Limited time offer. No credit card required.   Get My Free Report Click here to download 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

URL: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/delmar-pharmaceuticals-announces-issuance-new-patent-first-class-dna-targeting-agent-val-083/